Literature DB >> 22957790

Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells.

Davood Bashash1, Seyed H Ghaffari, Rooholah Mirzaee, Kamran Alimoghaddam, Ardeshir Ghavamzadeh.   

Abstract

Since unlimited proliferative potential has been identified as a major and, to date, therapeutically unexploited phenotypic hallmark of cancer, telomere maintenance mechanisms have been proposed as potential targets for new anticancer interventions. This study was aimed to investigate the effects of BIBR1532, the lead compound of non-nucleosidic inhibition of telomerase, on pre-B acute lymphoblastic leukemia (ALL) cells. BIBR1532 caused rapid cell death in Nalm-6 cells probably through transcriptional suppression of survivin-mediated c-Myc and human telomerase reverse transcriptase (hTERT) expression in a concentration-dependent manner. Moreover, our results also suggest that induced p73, up-regulated Bax/Bcl-2 molecular ratio and subsequent activation of caspase-3 may contribute to a direct short-term cytotoxic effect of high doses of BIBR1532, independent of long-term substantial telomere erosion-mediated cell cycle arrest.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22957790     DOI: 10.3109/10428194.2012.704034

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Multiple Pathways Control the Reactivation of Telomerase in HTLV-I-Associated Leukemia.

Authors:  Marcia Bellon; Christophe Nicot
Journal:  Int J Cancer Oncol       Date:  2015-06-02

Review 2.  In perspective: An update on telomere targeting in cancer.

Authors:  Eric T Sugarman; Gao Zhang; Jerry W Shay
Journal:  Mol Carcinog       Date:  2019-05-06       Impact factor: 4.784

3.  A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.

Authors:  Yi Shi; Lin Sun; Ge Chen; Dongyan Zheng; Li Li; Wanguo Wei
Journal:  Target Oncol       Date:  2015-04-29       Impact factor: 4.493

4.  Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells.

Authors:  C Lavanya; Manjunatha M Venkataswamy; M K Sibin; M M Srinivas Bharath; G K Chetan
Journal:  Cytotechnology       Date:  2018-03-15       Impact factor: 2.058

Review 5.  The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation.

Authors:  Limengmeng Wang; Haowen Xiao; Xing Zhang; Chong Wang; He Huang
Journal:  J Hematol Oncol       Date:  2014-08-20       Impact factor: 17.388

6.  Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.

Authors:  Andrea Celeghin; Silvia Giunco; Riccardo Freguja; Manuela Zangrossi; Silvia Nalio; Riccardo Dolcetti; Anita De Rossi
Journal:  Cell Death Dis       Date:  2016-12-29       Impact factor: 8.469

7.  Anti-Proliferative and Pro-Apoptotic Effects of Short-Term Inhibition of Telomerase In Vivo and in Human Malignant B Cells Xenografted in Zebrafish.

Authors:  Silvia Giunco; Manuela Zangrossi; Francesca Dal Pozzolo; Andrea Celeghin; Giovanni Ballin; Maria Raffaella Petrara; Aamir Amin; Francesco Argenton; Miguel Godinho Ferreira; Anita De Rossi
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

8.  The Small Molecule BIBR1532 Exerts Potential Anti-cancer Activities in Preclinical Models of Feline Oral Squamous Cell Carcinoma Through Inhibition of Telomerase Activity and Down-Regulation of TERT.

Authors:  Gennaro Altamura; Barbara Degli Uberti; Giorgio Galiero; Giovanna De Luca; Karen Power; Luca Licenziato; Paola Maiolino; Giuseppe Borzacchiello
Journal:  Front Vet Sci       Date:  2021-01-20

9.  In vitro characterization and rational analog design of a novel inhibitor of telomerase assembly in MDA MB 231 breast cancer cell line.

Authors:  Daniel Gomez; Diego Mengual Gómez; Romina Armando; Maia Cabrera; Roman Vilarullo; Patricio Chinestrad; Julian Maggio; Camila Paderta; Pablo Lorenzano Menna
Journal:  Oncol Rep       Date:  2022-09-14       Impact factor: 4.136

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.